Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Short-term Investments (2019 - 2025)

Opus Genetics has reported Short-term Investments over the past 11 years, most recently at $1000.0 for Q1 2025.

  • Quarterly Short-term Investments fell 80.0% to $1000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Mar 2025, down 80.0% year-over-year, with the annual reading at $2000.0 for FY2024, 86.67% down from the prior year.
  • Short-term Investments was $1000.0 for Q1 2025 at Opus Genetics, down from $2000.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $383000.0 in Q3 2021 and troughed at $1000.0 in Q1 2025.
  • The 5-year median for Short-term Investments is $22000.0 (2023), against an average of $73266.7.
  • The largest YoY upside for Short-term Investments was 69.39% in 2023 against a maximum downside of 89.11% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $219000.0 in 2021, then tumbled by 77.63% to $49000.0 in 2022, then tumbled by 69.39% to $15000.0 in 2023, then tumbled by 86.67% to $2000.0 in 2024, then crashed by 50.0% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRD's Short-term Investments are $1000.0 (Q1 2025), $2000.0 (Q4 2024), and $3000.0 (Q3 2024).